Gufic Biosciences Limited (BOM:509079)
India · Delayed Price · Currency is INR 370.05
+9.85 (2.73%)
At close: Jun 16, 2026
Gufic Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 9,440 | 8,198 | 8,067 | 6,906 | 7,792 | |
Revenue Growth (YoY) | 15.15% | 1.63% | 16.80% | -11.36% | 59.76% |
Cost of Revenue | 4,212 | 3,820 | 3,986 | 3,393 | 4,207 |
Gross Profit | 5,228 | 4,378 | 4,080 | 3,513 | 3,585 |
Selling, General & Admin | 1,517 | 1,307 | 1,133 | 940.25 | 913.47 |
Other Operating Expenses | 2,198 | 1,688 | 1,452 | 1,197 | 1,191 |
Operating Expenses | 4,023 | 3,205 | 2,755 | 2,360 | 2,294 |
Operating Income | 1,205 | 1,173 | 1,326 | 1,153 | 1,291 |
Interest Expense | -366.11 | -230.28 | -147.58 | -66.36 | -40.06 |
Interest & Investment Income | - | 15.74 | 14.13 | 14.13 | 18.8 |
Currency Exchange Gain (Loss) | - | -22.97 | 4.97 | -29.61 | 6.93 |
Other Non Operating Income (Expenses) | 26.57 | 4.46 | -17.63 | -4.56 | -8.97 |
EBT Excluding Unusual Items | 865.49 | 940.28 | 1,180 | 1,067 | 1,268 |
Gain (Loss) on Sale of Assets | - | 1.16 | -23 | 0.3 | 0.68 |
Pretax Income | 865.49 | 941.44 | 1,157 | 1,067 | 1,268 |
Income Tax Expense | 223.36 | 244.95 | 295.36 | 270.16 | 309.98 |
Earnings From Continuing Operations | 642.13 | 696.49 | 861.36 | 797.05 | 958.4 |
Minority Interest in Earnings | 0.02 | 0.01 | - | - | - |
Net Income | 642.15 | 696.5 | 861.36 | 797.05 | 958.4 |
Net Income to Common | 642.15 | 696.5 | 861.36 | 797.05 | 958.4 |
Net Income Growth | -7.80% | -19.14% | 8.07% | -16.84% | 116.68% |
Shares Outstanding (Basic) | 100 | 100 | 99 | 97 | 97 |
Shares Outstanding (Diluted) | 100 | 100 | 99 | 97 | 97 |
Shares Change (YoY) | 0.06% | 1.78% | 1.63% | - | - |
EPS (Basic) | 6.40 | 6.95 | 8.74 | 8.22 | 9.89 |
EPS (Diluted) | 6.40 | 6.95 | 8.74 | 8.22 | 9.89 |
EPS Growth | -7.86% | -20.53% | 6.33% | -16.85% | 116.80% |
Free Cash Flow | 137.87 | 470.42 | -1,202 | -2,142 | 187.86 |
Free Cash Flow Per Share | 1.37 | 4.69 | -12.20 | -22.09 | 1.94 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 |
Gross Margin | 55.38% | 53.41% | 50.58% | 50.87% | 46.01% |
Operating Margin | 12.77% | 14.31% | 16.44% | 16.70% | 16.57% |
Profit Margin | 6.80% | 8.50% | 10.68% | 11.54% | 12.30% |
Free Cash Flow Margin | 1.46% | 5.74% | -14.89% | -31.01% | 2.41% |
EBITDA | 1,513 | 1,310 | 1,422 | 1,307 | 1,430 |
EBITDA Margin | 16.03% | 15.98% | 17.63% | 18.92% | 18.36% |
D&A For EBITDA | 308.33 | 136.45 | 96.33 | 153.43 | 139.3 |
EBIT | 1,205 | 1,173 | 1,326 | 1,153 | 1,291 |
EBIT Margin | 12.77% | 14.31% | 16.44% | 16.70% | 16.57% |
Effective Tax Rate | 25.81% | 26.02% | 25.53% | 25.31% | 24.44% |
Revenue as Reported | 9,467 | 8,234 | 8,088 | 6,932 | 7,823 |
Advertising Expenses | - | 18.63 | 21.23 | 59.56 | 33.44 |